Study of EZN-2208 Pediatric Patients With Solid Tumors

Summary

The goal of this clinical research study is to find the highest tolerable dose of EZN-2208 that can be given to pediatric patients with Relapsed or Refractory Solid Tumors. The safety of the study drug and its effect on the disease will also be studied.

Timeline

Start

2010-02

Primary completion

2012-08

Completion

2013-01

Outcome

Outcome not reported

Stopped: “Program suspended and divested”

Drugs

Indications